Navigation Links
Delcath Systems Announces Second Quarter Progress Report Conference Call
Date:7/26/2010

NEW YORK, July 26 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that it will host a conference call to discuss its second quarter results and recent corporate developments on Thursday, July 29, 2010 at 4:30pm, ET. Eamonn Hobbs, President and Chief Executive Officer, and David McDonald, Chief Financial Officer, will host the call. The dial-in number for the conference call is 888-561-1799 for domestic participants and 480-629-9869 for international participants.

Individual investors are encouraged to submit their questions to management by 12:00 p.m. on the day of the call to tjohnson@delcath.com.  Management will respond to as many questions as time permits following prepared remarks.

To access the live webcast of the meeting, go to Delcath's website at www.delcath.com. A taped replay of the conference call will also be available beginning approximately one hour after the meeting's conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4338101#. An archived webcast will also be available at www.delcath.com.

About Delcath Systems

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers.  Delcath recently concluded a Phase III metastatic melanoma study, and the Company is currently conducting a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system.  For more information, please visit the Company's website at www.delcath.com.  

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug-delivery system for the treatment of other liver cancers and other organs, the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, actions by the FDA or other regulatory agencies  and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago
2. Delcaths Eamonn Hobbs to Ring NASDAQ Opening Bell
3. Delcath Systems Provides Update on Corporate Developments
4. Delcath Signs First Partner Agreement in Asia
5. Delcath Systems Begins Data Analysis of Phase III Trial
6. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
7. Professor Riccardo Lencioni Joins Delcath Systems Scientific Advisory Board
8. Delcath Systems Reports Substantial Progress
9. Delcath Systems Announces Completion of Public Offering
10. Delcath Systems, Inc. Prices $30.6 Million Stock Offering
11. Delcath Systems, Inc. Completes Phase III Study Enrollment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... -- Joe Marziani has joined VMS BioMarketing as senior vice president of sales, announced ... role, Marziani will lead the company,s business development and sales team, exploring new opportunities ... Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... 24, 2016 ... , la première endoprothèse à double thérapie ... l,intervention portant sur les membres inférieurs et ... OrbusNeich, entreprise mondiale spécialisée dans la fourniture ... vie, a élargi son portefeuille pour inclure ...
(Date:5/24/2016)... , May 24, 2016 Een ... verbindt, zodat zij collectief patiënten kunnen behandelen, hun kennis ... het idee achter de nieuwe en revolutionaire MDLinking App, ... de Nederlandse vaatchirurg dr. Hans Flu en oncologisch chirurg ... die inmiddels beschikbaar is, wordt op dinsdag 24 mei ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 26, 2016 , ... On May 23rd during the National Eye Institute’s “Healthy ... water advocate, was honored by Ashram, Inc. as the world’s foremost water visionary. , ... the banks of the Nile to fill their red clay pots with life-sustaining water.” ...
(Date:5/26/2016)... , ... May 26, 2016 , ... The introduction of ... ADDING PROTECTION TO YOUR HEAD ™”. , “We are proud to introduce ... the football front we have Brian Quick, wide receiver for Los Angeles who was ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... . With over 20 years of experience in leading technology and human resources ... years of university teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio ...
(Date:5/26/2016)... ... , ... May 2016 – Lips may be a central feature on our ... numbers of clients now ask about lip plumping and primping techniques and want tips ... Advanced Dermatology P.C. , The trend is a national one, with 2.4 ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... is happy to announce the launch of its brand equity product, Brandvantage. ... to reflect the dynamic landscape of modern consumer decision-making. The proprietary framework ...
Breaking Medicine News(10 mins):